"Kristina Ingvar is the right person to take on the responsibility for our regulatory and quality functions. Kristina's experience in the field, together with her leadership and market-oriented thinking will be of great value to us. At the same time, I would like to extend a big thank you to Carin Nilsson-Thorell who has meant a lot to the company and its journey for many years and wish her all the best for the future" says Emil Billbäck, BONESUPPORT's CEO.
About BONESUPPORT™
BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform CERAMENT (https://www.bonesupport.com/en-eu/cerament™/). The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver and a Premarket approval filing with the FDA (USA) for CERAMENT G (https://www.bonesupport.com/en-eu/ceramentg/) is planned in 2021. The company is based in Lund, Sweden, and the net sales amounted to SEK 97 million in 2018. Please visit www.bonesupport.com (https://www.bonesupport.com/en-eu/) for more information.
BONESUPPORT and CERAMENT are registered trademarks (https://www.bonesupport.com/trademarks.html) of BONESUPPORT AB.
For more information contact:
BONESUPPORT AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70
Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com
Cord Communications
Charlotte Stjerngren
+46 (0)708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se